Heart failure & cardiomyopathies
The impact of mavacamten dosing on wall thickness regression: an insight from longer term follow-up based on genetic profile
Authors' conclusion
We hypothesize that this lower dosing attenuated the long-term benefit of mavacamten in genetically positive patients.
Study context
- Population
- Patients treated with mavacamten
- Exposure
- Genetically positive vs genetically negative patients on mavacamten
- Outcome
- LV wall thickness regression
- Follow-up
- Long-term
Main finding
As reported in the abstract
- Less favorable remodeling (LV wall thickness regression) in genetically positive vs genetically negative patients, despite better early response
Observational data: associations, not effects.
Further findings
Mavacamten dose
- Majority of genetically positive patients maintained on only 2.5 mg due to early robust response
Original publication
The impact of mavacamten dosing on wall thickness regression: an insight from longer term follow-up based on genetic profile. Am Heart J. Published 30 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →